FI3389699T3 - Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja - Google Patents

Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja Download PDF

Info

Publication number
FI3389699T3
FI3389699T3 FIEP16876612.9T FI16876612T FI3389699T3 FI 3389699 T3 FI3389699 T3 FI 3389699T3 FI 16876612 T FI16876612 T FI 16876612T FI 3389699 T3 FI3389699 T3 FI 3389699T3
Authority
FI
Finland
Prior art keywords
chimeric
antibodies
seq
human monoclonal
ctla4 antibodies
Prior art date
Application number
FIEP16876612.9T
Other languages
English (en)
Finnish (fi)
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoc4 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoc4 Inc filed Critical Oncoc4 Inc
Application granted granted Critical
Publication of FI3389699T3 publication Critical patent/FI3389699T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP16876612.9T 2015-12-15 2016-12-14 Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja FI3389699T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562267735P 2015-12-15 2015-12-15
US201662309169P 2016-03-16 2016-03-16
US201662359036P 2016-07-06 2016-07-06
PCT/US2016/066698 WO2017106372A1 (en) 2015-12-15 2016-12-14 Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
FI3389699T3 true FI3389699T3 (fi) 2024-05-28

Family

ID=59057509

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16876612.9T FI3389699T3 (fi) 2015-12-15 2016-12-14 Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja

Country Status (25)

Country Link
US (3) US10618960B2 (enExample)
EP (2) EP3389699B1 (enExample)
JP (5) JP6858779B2 (enExample)
KR (2) KR20250108763A (enExample)
CN (1) CN108430499B (enExample)
AU (3) AU2016370648B2 (enExample)
CA (1) CA3006984C (enExample)
DK (1) DK3389699T5 (enExample)
ES (1) ES2979210T3 (enExample)
FI (1) FI3389699T3 (enExample)
HR (1) HRP20240719T1 (enExample)
HU (1) HUE066907T2 (enExample)
IL (3) IL259988B2 (enExample)
LT (1) LT3389699T (enExample)
MX (3) MX2018006925A (enExample)
MY (1) MY186974A (enExample)
PL (1) PL3389699T3 (enExample)
PT (1) PT3389699T (enExample)
RS (1) RS65703B1 (enExample)
SG (1) SG11201804969PA (enExample)
SI (1) SI3389699T1 (enExample)
SM (1) SMT202400211T1 (enExample)
TW (1) TWI739781B (enExample)
WO (1) WO2017106372A1 (enExample)
ZA (1) ZA201804077B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
EP3515489B1 (en) 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
AU2018366199A1 (en) * 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
KR102834864B1 (ko) * 2018-02-02 2025-07-16 온코씨4, 아이앤씨. 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체
SG11202007018QA (en) * 2018-02-02 2020-08-28 Oncoimmune Inc Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019233413A1 (en) * 2018-06-05 2019-12-12 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Dimer and use thereof
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CN114008071B (zh) 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
US12559565B2 (en) 2020-04-13 2026-02-24 Biosion Inc. Antibodies binding CTLA4 and uses thereof
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022169269A1 (ko) * 2021-02-03 2022-08-11 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
JP7345889B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
AU2022361768A1 (en) * 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023057994A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
MX2024004429A (es) 2021-10-29 2024-05-06 Oncoc4 Inc Regimenes de dosificacion del anticuerpo anti-ctla-4.
US20260035484A1 (en) * 2021-10-29 2026-02-05 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
JP2025531229A (ja) 2022-09-16 2025-09-19 オンコシーフォー、インク． 腺様嚢胞がんを処置するための抗ｃｔｌａ－４抗体の使用
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
KR20260005250A (ko) 2023-04-28 2026-01-09 온코씨4, 아이앤씨. 항-ctla-4 항체와 항-pd-1 항체의 조합 및 이의 치료적 용도
EP4724498A2 (en) * 2023-06-09 2026-04-15 The Regents of the University of California Methods for identifying and correcting tumor humoral immune dysfunction
AU2024402568A1 (en) 2023-12-22 2026-07-09 BioNTech SE Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
JPWO2025234450A1 (enExample) * 2024-05-08 2025-11-13
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026041780A2 (en) 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment
WO2026057739A1 (en) 2024-09-12 2026-03-19 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
WO2026125485A1 (en) 2024-12-11 2026-06-18 BioNTech SE Anti-ctla4 antibodies for treating non-small cell lung cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
WO2006029219A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
EP1793857A4 (en) * 2004-09-08 2008-09-03 Univ Ohio State Res Found COMBINED THERAPY USING ANTI-CTLA4 ANTI-4-1BB ANTIBODIES
SG156643A1 (en) 2004-10-15 2009-11-26 Verisign Inc One time password
CA2591914C (en) 2005-01-24 2017-04-25 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CN101628940B (zh) * 2008-07-15 2011-11-23 中国科学院生物物理研究所 一种单克隆抗体及其应用
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
US20150079100A1 (en) * 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
EP3515489B1 (en) 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof

Also Published As

Publication number Publication date
EP3389699B1 (en) 2024-05-01
IL259988B2 (en) 2023-02-01
CA3006984A1 (en) 2017-06-22
PT3389699T (pt) 2024-06-04
DK3389699T5 (da) 2024-09-23
AU2023203169B2 (en) 2025-11-27
ES2979210T3 (es) 2024-09-24
CN116063492A (zh) 2023-05-05
IL296354A (en) 2022-11-01
IL296354B2 (en) 2024-07-01
MX2018006925A (es) 2018-08-01
ZA201804077B (en) 2019-09-25
DK3389699T3 (da) 2024-05-13
KR20180086219A (ko) 2018-07-30
EP3389699A4 (en) 2019-07-10
SI3389699T1 (sl) 2024-07-31
JP2025160458A (ja) 2025-10-22
US20190127468A1 (en) 2019-05-02
AU2026200849A1 (en) 2026-02-26
JP7286845B2 (ja) 2023-06-05
KR102830926B1 (ko) 2025-07-08
JP2023106547A (ja) 2023-08-01
CN108430499B (zh) 2022-07-19
EP4374926A3 (en) 2024-08-07
JP6858779B2 (ja) 2021-04-14
US20230391870A1 (en) 2023-12-07
JP2022123049A (ja) 2022-08-23
HUE066907T2 (hu) 2024-09-28
TWI739781B (zh) 2021-09-21
WO2017106372A1 (en) 2017-06-22
NZ743013A (en) 2025-03-28
AU2016370648A1 (en) 2018-06-21
CN108430499A (zh) 2018-08-21
SG11201804969PA (en) 2018-07-30
EP4374926A2 (en) 2024-05-29
CA3006984C (en) 2023-10-17
IL296354B1 (en) 2024-03-01
IL259988A (en) 2018-07-31
LT3389699T (lt) 2024-06-10
HRP20240719T1 (hr) 2024-09-13
US12473362B2 (en) 2025-11-18
SMT202400211T1 (it) 2024-07-09
MX2025001302A (es) 2025-03-07
TW201731877A (zh) 2017-09-16
KR20250108763A (ko) 2025-07-15
MX2025001300A (es) 2025-03-07
JP7790837B2 (ja) 2025-12-23
RS65703B1 (sr) 2024-07-31
IL310404A (en) 2024-03-01
PL3389699T3 (pl) 2024-07-22
AU2023203169A1 (en) 2023-06-15
US20200283526A1 (en) 2020-09-10
JP7904374B2 (ja) 2026-08-12
IL259988B (en) 2022-10-01
MY186974A (en) 2021-08-26
BR112018012113A2 (en) 2018-12-04
JP2019510733A (ja) 2019-04-18
EP3389699A1 (en) 2018-10-24
JP2021100957A (ja) 2021-07-08
AU2016370648B2 (en) 2023-03-09
US11629188B2 (en) 2023-04-18
US10618960B2 (en) 2020-04-14

Similar Documents

Publication Publication Date Title
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
FI4050034T3 (fi) Cd3:een sitoutuvia vasta-aineita
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
IL258215B (en) Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody
ZA202001251B (en) Interleukin-21 muteins and methods of treatment
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
FI3303396T3 (fi) Vasta-aineita ox40:ää vastaan ja niiden käyttöjä
RU2017105120A (ru) Cd3-связывающий домен
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
NZ715896A (en) Humanized or chimeric cd3 antibodies
JP2018508483A5 (enExample)
JP2018501197A5 (enExample)
ZA201901379B (en) Antigen binding protein against her3
WO2017060322A3 (en) Ptefb-inhibitor-adc
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
EA201890613A1 (ru) Полипептиды, связывающие cd3
RU2430111C3 (ru) Молекулы антител с улучшенными свойствами
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2014502955A5 (enExample)